Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes
Executive Summary
Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.
You may also be interested in...
Medicare Coverage For Aduhelm Conditioned On Randomized Trial Would Be ‘Unusual’ – McClellan
Former CMS chief Mark McClellan discusses what kind of study requirements Medicare might impose if it decides to only cover the new Alzheimer’s drug if in the context of further evidence generation.
Medicare Coverage Analysis Of Alzheimer’s Drugs Begins With Focus On Outcomes, Patient Eligibility
Proposed reimbursement decision to be released by 12 January 2022, with a final decision the following April. Biogen's Aduhelm expected to be covered in the interim. Medicare will not consider the cost of treatment in the analysis, but cost may have been a factor in initiating the process.
Lilly Amyvid Lawsuit: CMS Used Tougher Standard For Alzheimer's Scan
A lawsuit filed by Medicare beneficiaries with support from the manufacturer of the imaging agent says diagnostic scans should not be required to show change in disease management or outcomes for Medicare coverage. CMS limits coverage to use as part of a clinical trial – and only one trial has been approved.